Jennifer J. Huang

Hematology
1100 Fairview Ave N
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Coordinated expansion of CD163⁺ monocytes and immature CD177⁺ neutrophils marks severe neurotoxicity after CD19 CAR T cell therapy.

Coordinated expansion of CD163⁺ monocytes and immature CD177⁺ neutrophils marks severe neurotoxicity after CD19 CAR T cell therapy.

Journal: bioRxiv : the preprint server for biology
Published: July 17, 2026

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

Journal: Blood advances
Published: April 07, 2026

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Journal: Blood cancer journal
Published: March 06, 2026

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Journal: Blood advances
Published: February 18, 2026

Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.

Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.

Journal: JCO clinical cancer informatics
Published: January 14, 2026

Steroid-sparing strategies for managing immune-related adverse events.

Steroid-sparing strategies for managing immune-related adverse events.

Journal: Journal for immunotherapy of cancer
Published: December 31, 2025

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Journal: Haematologica
Published: December 19, 2025

Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study.

Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study.

Journal: Blood advances
Published: November 17, 2025

Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.

Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.

Journal: Blood advances
Published: November 17, 2025

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

Journal: Blood
Published: September 05, 2025

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

Journal: Blood
Published: September 05, 2025

First-line Therapy: Time-Limited Venetoclax Doublet Therapy.

First-line Therapy: Time-Limited Venetoclax Doublet Therapy.

Journal: Hematology/oncology clinics of North America
Published: July 11, 2025
Showing 1-12 of 22

Last Updated: 09/26/2026